FDA Granted Breakthrough Status to Colorectal Cancer Drug
A new combination therapy has shown promise for patients with refractory metastatic colorectal cancer.
Updated on Oct. 7, 2026 in Cancer
Live Poll
Do you trust that FDA breakthrough designations significantly improve patient access to effective new cancer treatments?
The FDA has granted breakthrough therapy designation to the experimental drug telisotuzumab adizutecan, known as Temab-A, when combined with bevacizumab. This status is intended to expedite the development of treatments for patients with refractory metastatic colorectal cancer who have exhausted standard options.
Why it matters
This designation recognizes clinical data suggesting the combination could offer improved outcomes for patients with limited treatment alternatives. It aims to accelerate the availability of a new therapeutic approach for individuals managing advanced disease.
In a Phase 1 study, the 2.4 mg/kg dose of Temab-A plus bevacizumab yielded a median progression-free survival of 6.8 months, compared to 4.2 months for those on standard-of-care. Adjudicated ILD/pneumonitis occurred in 5 percent of patients receiving the study drug.
The players
FDA
The federal agency responsible for protecting public health by regulating the safety and efficacy of medical products.
The details
Temab-A is an investigational drug that, in combination with bevacizumab, targets metastatic colorectal cancer in patients previously treated with fluoropyrimidine, irinotecan, oxaliplatin, and anti-VEGF therapy. The regimen uses a safety lead-in period followed by dose-optimization to balance therapeutic efficacy with side-effect management. Researchers are now evaluating these findings in the Phase 3 AndroMETa-CRC trial.
Timeline
May 29, 2025: Data cutoff for the Phase 1 study M21-404.
2025: Results from the study were presented at the ESMO Congress.
October 7, 2026: The FDA officially granted breakthrough therapy designation.
Health Landscape
This designation marks a significant step in the development of targeted therapies for patients with refractory colorectal cancer. It builds on the AndroMETa-CRC phase 3 clinical trial, which aims to provide definitive evidence for the drug's role against current standards of care.
Patients currently navigating treatment for metastatic colorectal cancer should discuss whether clinical trials like the AndroMETa-CRC study might be an appropriate option. These conversations with your oncologist are essential for understanding how new breakthrough designations may eventually impact your care pathway.
The takeaway
Breakthrough designation is a regulatory tool designed to expedite the evaluation of promising new cancer therapies. Patients interested in these treatments should consult their physician regarding eligibility for ongoing clinical research studies.
Further reading
Learn more about the latest developments in Cancer research and treatments.
More information
Review the official AndroMETa-CRC phase 3 trial details for more on the study design.
Live Poll
Do you trust that FDA breakthrough designations significantly improve patient access to effective new cancer treatments?
